ReviewJournal of clinical medicine2015
Myogenic Precursors from iPS Cells for Skeletal Muscle Cell Replacement Therapy.
Review in Journal of clinical medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Regenerative Medicine: Advanced Therapy for Muscle Tissue Restoration.International journal of molecular sciences · 2026Review
- Control of satellite cell function in muscle regeneration and its disruption in ageing.Nature reviews. Molecular cell biology · 2022Review
- Contribution of muscle satellite cells to sarcopenia.Frontiers in physiology · 2022Review
- Current Strategies for the Regeneration of Skeletal Muscle Tissue.International journal of molecular sciences · 2021Review
- Treatment of Stress Urinary Incontinence with Muscle Stem Cells and Stem Cell Components: Chances, Challenges and Future Prospects.International journal of molecular sciences · 2021Review
- Recent Advances in Scaffolding from Natural-Based Polymers for Volumetric Muscle Injury.Molecules (Basel, Switzerland) · 2021Review
- Article
- Engraftment of human induced pluripotent stem cell-derived myogenic progenitors restores dystrophin in mice with duchenne muscular dystrophy.Biological research · 2020Article
- Micropatterned substrates with physiological stiffness promote cell maturation and Pompe disease phenotype in human induced pluripotent stem cell-derived skeletal myocytes.Biotechnology and bioengineering · 2019Article
- iPSCs: A powerful tool for skeletal muscle tissue engineering.Journal of cellular and molecular medicine · 2019Review
- Review
- Autologous Cell Therapy Approach for Duchenne Muscular Dystrophy using PiggyBac Transposons and Mesoangioblasts.Molecular therapy : the journal of the American Society of Gene Therapy · 2018Article
- Human iPSC Models to Study Orphan Diseases: Muscular Dystrophies.Current stem cell reports · 2018Review
- Abnormalities in Skeletal Muscle Myogenesis, Growth, and Regeneration in Myotonic Dystrophy.Frontiers in neurology · 2018Review
- Current Progress and Challenges for Skeletal Muscle Differentiation from Human Pluripotent Stem Cells Using Transgene-Free Approaches.Stem cells international · 2018Review
- Skeletal muscle generated from induced pluripotent stem cells - induction and application.World journal of stem cells · 2017Review
- Activation of the NLRP3 Inflammasome Is Associated with Valosin-Containing Protein Myopathy.Inflammation · 2017Article
- Induction of Acute Skeletal Muscle Regeneration by Cardiotoxin Injection.Journal of visualized experiments : JoVE · 2017Article
- RETRACTED: Myogenic differentiation of VCP disease-induced pluripotent stem cells: A novel platform for drug discovery.PloS one · 2017Article
- Generation of human muscle fibers and satellite-like cells from human pluripotent stem cells in vitro.Nature protocols · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The use of adult myogenic stem cells as a cell therapy for skeletal muscle regeneration has been attempted for decades, with only moderate success. Myogenic progenitors (MP) made from induced pluripotent stem cells (iPSCs) are promising candidates for stem cell therapy to regenerate skeletal muscle since they allow allogenic transplantation, can be produced in large quantities, and, as compared to adult myoblasts, present more embryonic-like features and more proliferative capacity in vitro, which indicates a potential for more self-renewal and regenerative capacity in vivo. Different approaches have been described to make myogenic progenitors either by gene overexpression or by directed differentiation through culture conditions, and several myopathies have already been modeled using iPSC-MP. However, even though results in animal models have shown improvement from previous work with isolated adult myoblasts, major challenges regarding host response have to be addressed and clinically relevant transplantation protocols are lacking. Despite these challenges we are closer than we think to bringing iPSC-MP towards clinical use for treating human muscle disease and sporting injuries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.